Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference

BOSTON--(BUSINESS WIRE)-- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on lead program STAR-0215 at the upcoming virtual Jefferies London Healthcare Conference.

The presentation will be available to all conference attendees on-demand beginning on Thursday, November 18, at 3:00am ET through Friday, November 19, at 12:00pm ET.

A webcast of the event can be accessed from the Investors section of and at the following link: An archived replay will be available for 30 days following the event.

About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Learn more about our company on our website,, or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.



Investor relations:
Andrea Matthews

Elizabeth Higgins


Source: Astria Therapeutics, Inc.

Back to news